Skip to main content
. Author manuscript; available in PMC: 2014 May 29.
Published in final edited form as: Leukemia. 2010 Sep 16;24(12):2100–2109. doi: 10.1038/leu.2010.212

Figure 3. Effects of SCM on kinase inhibitor-treated leukemia cells in vitro.

Figure 3

(A) MOLM13-luc+ cells treated for approximately 3 days by PKC412 in the absence and presence of SCM. Media was collected from HS-5 stromal cells after 1 week from an already-established monolayer. HS-5 stromal cells were originally seeded 12 days prior to removal of conditioned media. Cells were then further cultured in fresh media for 7 days. Conditioned media was then collected for use in this study. (B) Approximately 3-day treatment of Ba/F3-FLT3-ITD cells in the presence and absence of SCM from primary murine stroma. Primary stromal cells were seeded following femur flush from C67BL/6J mice. SCM was collected and pooled from an already-established mouse primary stroma monolayer. Cells were cultured for 16 days in fresh media prior to media pool and collection. (C) Proliferation studies of MOLM13-luc+ cells treated for approximately 3 days by PKC412+/−LCL161 in the presence of HS-5 SCM. Cell counts were obtained via Trypan Blue exclusion. (D) Viability assays corresponding to study shown in C. Data points shown are the percentage of viable cells (as determined by Annexin-V-Fluos Staining) shown as a percent of untreated controls.